Veru announces the presentation of a phase 1b/2 clinical study update for sabizabulin (veru-111) in men with metastatic castration resistant prostate cancer at the 2021 european association of urology annual congress

Miami, june 28, 2021 (globe newswire) -- veru inc. (nasdaq: veru), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancers, today announced updated clinical results from the ongoing phase 1b/2 clinical study of sabizabulin (veru-111), an oral cytoskeleton disruptor being evaluated for the treatment of metastatic castration resistant prostate cancer in men who progressed on an androgen receptor targeting agent, were accepted for presentation at the european association of urology 36th annual congress. the congress is being held virtually from july 8-12, 2021.
VERU Ratings Summary
VERU Quant Ranking